



**VGX Pharmaceuticals Co-Founder Professor David B. Weiner
to Chair International Scientific Congress**

Blue Bell, PA – May 21, 2007 –

VGX Pharmaceuticals Inc. (VGX) announced today that Professor David B. Weiner of the University of Pennsylvania will serve as Conference Chairman of the Third International Conference on DNA Vaccines this week in Malaga, Spain. Professor Weiner is a pioneer in the field of DNA vaccines and a VGX co-founder.

The three-day conference, which begins May 23, will focus on the development of DNA and genetic immunization and will include international delegates from biotechnology companies, major pharmaceutical companies, academic institutions, and government labs. Over the last two decades, DNA vaccines have become a potent means of providing immune responses or protective immunity against viruses, bacteria and parasites in many species from fish to primates, including humans. DNA vaccines, comprising plasmid DNA encoding proteins from pathogens, allergens, and tumors, are being evaluated as prophylactic vaccines and therapeutic treatments for infectious diseases, allergies and cancer. The use of DNA as a means of vaccination offers potential benefits in protective efficacy, cross-strain applicability, development speed and manufacturing cost compared with conventional vaccines. DNA vaccines are known to be particularly effective in inducing killer T-cell responses which are an important ingredient in fighting infections.

VGX Pharmaceuticals is developing a new generation of DNA vaccines which utilize synthetic consensus sequences and antigens for key HIV, HCV, HPV, and Influenza proteins that offer coverage across different viral sub-types or taxonomic groups. Pre-clinical studies have shown that immunization of mice and non-human primates using the consensus DNA constructs for each virus elicits an immune response against multiple sub-types of the HIV, HCV, HPV, or Influenza viruses respectively. VGX is also developing its proprietary CELLECTRA™ DNA Delivery Device as a novel adaptive electroporation device to deliver its DNA vaccine candidates.

Dr. Weiner will deliver the Opening Plenary presentation entitled "DNA vaccines: Where are we now? – An overview on progress and significant developments," at 9:00 a.m. on May 23.

Dr. Ruxandra Draghia-Akli, VGX Vice President, Immune Therapeutics Research, will serve as a Session Moderator for the Electroporation Session and will deliver a presentation entitled, "Enhanced immune responses to DNA vaccines via electroporation." Dr. C. Jo White, VGX Chief Medical Officer, will also serve as a Session Moderator for the HIV Development Session.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecules and biologics product candidates for the treatment of infectious diseases, cancer and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection, both of which are currently in Phase II clinical trials. In addition, Phase I clinical trials will be initiated in 2007 for VGX-150 for the treatment of Melanoma and VGX-1027 for inflammatory diseases. VGX's research pipelines include new generation of DNA vaccines and therapeutics as well as CELLECTRA™, a proprietary DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com